PHARMACY

Lupin acquires Symbiomix Therapeutics

BY David Salazar

MUMBAI, India — Lupin’s U.S. subsidiary’s latest acquisition is set to strengthen its pipeline for gynecologic drugs. The company has acquired Symbiomix Therapeutics for $150 million, which includes an upfront payment of $50 million and closed today.

With the acquisition, Lupin brings into its portfolio the Symbiomix’s Solosec franchise, expanding its women’s health specialty business, currently anchored by Lupin’s Methergine tablets. Solosec oral granules — a single-dose treatment for bacterial vaginosis — was approved by the Food and Drug Administration in mid-September and is set to be launched mid-2018. Having been designated by the FDA as a Qualified Infectious Disease Product, Solosec is eligible for 10 years of U.S. exclusivity, the company said.

“We are delighted to complete the acquisition of Symbiomix and its Solosec brand, which immediately expands Lupin’s U.S. women’s health specialty business into the highly-complementary gynecological infection sector,” Lupin CEO Vinita Gupta said. “This transaction is an important milestone in the evolution of our Specialty business and gives Lupin a new therapeutic to bring to obstetricians and gynecologists to treat a serious health condition they see frequently in their practices.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Diplomat to dispense Verzenio

BY David Salazar

FLINT, Mich. — Diplomat Pharmacy has begun filling prescriptions for patients prescribed the recently approved breast cancer treatment Verzenio (abemaciclib). The drug was approved to treat certain cases of advanced or metastatic breast cancer, either alone or in combination with Faslodex.

"This therapy represents yet another step forward in the way the healthcare community approaches treating advanced stages of this disease,” Diplomat president Joel Saban said. “We are proud to support patients dealing with breast cancer by dispensing VERZENIO.”

The American Cancer Society projects that more than 250,000 breast cancer diagnoses will be made in 2017.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Bartell taps LexisNexis Risk Solutions, eRx Network for prescriber validation

BY David Salazar

SEATTLE — Bartell Drugs has become the first user of the strategic alliance between LexisNexis Risk Solutions and eRx Network for its prescriber validation. The pharmacy chain will leverage LexisNexis VerifyRx to perform real-time prescription compliance checks within their existing workflows.

"We were ready to take the next step in prescriber compliance and needed a turnkey solution that would not take resources away from our focus on patients," Bartell Drugs SVP pharmacy Peter Koo said. "The VerifyRx solution enables Bartell to take advantage of timely, accurate and comprehensive prescriber data via the LexisNexis Provider Data MasterFile, using eRx Network's connectivity to implement a solution directly within our pharmacy workflow."

VerifyRx lets pharmacies use the real-time connectivity of eRx Network and LexisNexis’ provider validation service on more than 8.5 million providers. It doesn’t require maintenance or IT integration efforts from the pharmacy chain, the companies said.

“We are pleased to be partnering with Bartell to deliver the vast capabilities of VerifyRx and the value provided by the seamless integration with the eRx Network,” LexisNexis Risk Solutions VP sales, pharmacy, Craig Ford said. “Verifying prescriber data in the workflow process is critical to pharmacies. Our strategic alliance has enabled us to respond to the needs of Bartell and other chains to deliver a leading, compliance-driven solution while using their existing connectivity.”

Other features include such risk mitigation features as a custom user interface and reporting tools.

"The combination of eRx Network's reliable network and the comprehensive prescriber compliance solution of LexisNexis Health Care will help make it easier and more efficient for Bartell to meet compliance requirements through its entire chain of stores," eRX Network SVP Richard Brook said. "We are confident that the implementation of our combined solutions will add value to Bartell's processes without causing any disruption to their workflows or increases to their operational costs or development efforts."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?